ContraVir Pharmaceuticals Announces Participation at the Discovery on Target 2017 Conference in Boston
September 19 2017 - 6:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
targeted antiviral therapies, announced today it will be featured
at a symposium discussion titled “Targeting HBV.”
Robert T. Foster, PharmD, PhD, Chief Scientific Officer of
ContraVir, will make an oral presentation entitled, “Exploring the
Cyclophilin Inhibitor Mode of Action in HBV.” This talk will
highlight CRV431, the company’s cyclophilin
inhibitor.
Event: Discovery on
Target 2017, New Drug Development for Hepatitis B and Other
Infectious Diseases
Date: Monday,
September 25, 2017
Time: 4:00 – 4:30PM
(Eastern Time)
Location: The Westin
Copley, Boston, MA
About CRV431
CRV431 is a non-immunosuppressive analog of cyclosporine A (CsA)
whose primary biochemical action is inhibition of cyclophilin
isomerase activity, playing a key role in protein folding. Other
viruses such as HIV-1 and HCV, similarly use cyclophilin for their
replication. CRV431 shows potential in experimental models to
complement current hepatitis B treatments by reducing multiple
markers of infection including HBV DNA, HBsAg, HBx, HBeAg, and HBV
uptake by cells. Studies have also demonstrated that CRV431
possesses anti-fibrotic activity which may further curb progression
of liver disease in patients.About CRV431
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the
development and commercialization of targeted antiviral therapies
with a specific focus on developing a potentially curative therapy
for hepatitis B virus (HBV). The Company is developing two novel
anti-HBV compounds with complementary mechanisms of action. TXL™
currently in Phase 2, is designed to deliver high intrahepatic
concentrations of TFV, while minimizing off-target side-effects
caused by high levels of circulating TFV. CRV431, the other
anti-HBV compound, is a next-generation cyclophilin inhibitor with
a unique structure that increases its potency and selective index
against HBV. ContraVir is also developing Valnivudine™, an orally
available nucleoside analogue prodrug; Valnivudine™ is currently in
Phase 3 for the treatment of herpes zoster. In addition to
direct antiviral activity, Phase 2 data suggest that Valnivudine™
has the potential to reduce the incidence of debilitating
shingles-associated pain known as post-herpetic neuralgia
(PHN). For more information visit www.contravir.com.
Forward Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast,"
"estimated" and "intend," among others. These forward-looking
statements are based on ContraVir's current expectations and actual
results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, substantial competition; our ability to continue as
a going concern; our need for additional financing; uncertainties
of patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir does
not undertake an obligation to update or revise any forward-looking
statement. Investors should read the risk factors set forth in
ContraVir's Form 10-K for the year ended June 30, 2016 and other
periodic reports filed with the Securities and Exchange
Commission.
For further information, please contact:
Sharen Pyatetskaya Director of Investor Relations
sp@contravir.com; (732) 902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Sep 2023 to Sep 2024